The stock reached $15.34 in recent trading, a significant bounce that follows a period of heavy volatility. Earlier in the session, Sutro hit a 52-week high of $20.20, though the shares have declined approximately 16% over the last year.

Institutional Backing and Capital Use

The offering saw participation from several prominent healthcare investors, including BVF Partners, Samsara BioCapital, Affinity Asset Advisors, and Acuta Capital Partners. Sutro confirmed that it is providing all shares in the transaction, which is expected to close on Wednesday.

Management plans to deploy the proceeds, alongside existing cash and marketable securities, toward general corporate purposes. This capital injection provides the oncology specialist with additional runway as it matures its clinical programs.